INS and Hypoglycemia: In this real-world study over 18 months of follow-up, treatment with IDegLira resulted in a greater reduction in HbA1c (MD 0.6% [6.6 mmol/mol] lower), a relative reduction in body weight (MD 6.7 kg lower), a lower insulin dose (MD 31.8 IU/day lower), and an 82% lower risk of hypoglycaemia when compared with ICT.